Search | Clinical Trials Finder

Conditions: SARS-CoV-2
Interventions: mRNA-1273, mRNA-1283, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Conditions: Overactive Bladder
Interventions: (VERV™ System), Sham version of (VERV™ System); Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more

Conditions: Persistent Developmental Stuttering
Interventions: Pagoclone; Drug
Lead sponsor: Pharmacology Research Institute; Other
Eligibility: 18 Years to 65 Years
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Riverside, California

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Edecesertib, Edecesertib Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Phoenix, Arizona • Fremont, California • Aurora, Colorado + 9 more

Conditions: Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions: Alogliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 5,380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 292
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more

Conditions: Mucopolysaccharidosis I, Hurlers Syndrome, Hurler-Scheie Syndrome
Interventions: rhIDU (recombinant human-Alpha-L-Iduronidase), Placebo; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 5 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Sciatica
Interventions: CEP-37247, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 20
States / cities: La Mesa, California • Laguna Hills, California • Pasadena, California + 15 more

Conditions: Endometriosis
Interventions: HMI-115, Placebo; Drug
Lead sponsor: Hope Medicine (Nanjing) Co., Ltd; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Draper, Utah • Norfolk, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: ipragliflozin, Metformin, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Birmingham, Alabama • Haleyville, Alabama • Mesa, Arizona + 33 more

Conditions: Obesity
Interventions: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more

Conditions: Migraine Headache
Interventions: Erenumab 70 mg, Erenumab 140 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 32
States / cities: Cerritos, California • Colton, California • Los Angeles, California + 28 more

Conditions: Arthritis, Psoriatic
Interventions: Placebo, RO5310074; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Los Angeles, California • Miami, Florida + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anaheim, California • Escondido, California • Riverside, California + 45 more

Conditions: Breast Carcinoma
Interventions: Counseling, Written materials; Behavioral
Lead sponsor: American Scitech International; Other
Eligibility: 25 Years to 85 Years · Female only
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Englishtown, New Jersey

Conditions: Cyclic Vomiting Syndrome
Interventions: Active percutaneous electrical nerve field stimulation, Sham percutaneous electrical nerve field stimulation; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cystic Fibrosis
Interventions: GLPG2222 50 mg, GLPG2222 100 mg, Placebo, GLPG2222 200 mg, GLPG2222 400 mg; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 7
States / cities: Chatom, Alabama • Little Rock, Arkansas • Orlando, Florida + 4 more

Conditions: SARS-CoV2, COVID-19
Interventions: VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years and older
Enrollment: 5,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 145
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more

Conditions: Pre-eclampsia
Interventions: Anti-digoxin antibody (FAB fragment), sodium chloride; Drug · Other
Lead sponsor: BTG International Inc.; Other
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more

Conditions: Rheumatoid Arthritis
Interventions: AMG 357, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Duncansville, Pennsylvania • Dallas, Texas

Conditions: Panic Disorder
Interventions: placebo, alprazolam XR; Other · Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 3
States / cities: Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin

Conditions: Erectile Dysfunction
Interventions: Placebo, Levitra (Vardenafil, BAY38-9456); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 12
States / cities: Phoenix, Arizona • Beverly Hills, California • Laguna Hills, California + 9 more

Conditions: Sickle Cell Anemia, Thalassemia
Interventions: L-Glutamine, Placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Torrance, California

Conditions: Actinic Keratosis
Interventions: Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 20 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

A Study of RO5310074 in Patients With Psoriatic Arthritis

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

A Study of Auricular Neurostimulation for Children With Cyclic Vomiting Syndrome

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)

L-Glutamine Therapy for Sickle Cell Anemia

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis